display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
immune chekpoint inhibitors
Immune checkpoint association
nivolumab plus ipilimumab STIMULI

Study type: